Uy Ear
Stock Analyst at Mizuho
(4.13)
# 471
Out of 5,182 analysts
83
Total ratings
48.08%
Success rate
17.39%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintains: Outperform | $10 → $19 | $7.64 | +148.69% | 3 | Mar 20, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $26 → $31 | $21.49 | +44.25% | 10 | Mar 13, 2026 | |
| QURE uniQure | Upgrades: Outperform | $12 → $35 | $19.13 | +82.96% | 8 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $23.35 | +49.89% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $21.95 | +59.45% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $131.78 | +32.80% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $5.33 | +256.47% | 4 | Dec 2, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $33.38 | +34.81% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $29.78 | +88.05% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $29.03 | +192.85% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.20 | +545.16% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $227.19 | -82.39% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.94 | +240.14% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.80 | +66.67% | 2 | Mar 1, 2023 |
Relmada Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $10 → $19
Current: $7.64
Upside: +148.69%
Sarepta Therapeutics
Mar 13, 2026
Maintains: Outperform
Price Target: $26 → $31
Current: $21.49
Upside: +44.25%
uniQure
Mar 11, 2026
Upgrades: Outperform
Price Target: $12 → $35
Current: $19.13
Upside: +82.96%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $23.35
Upside: +49.89%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $21.95
Upside: +59.45%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $131.78
Upside: +32.80%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $5.33
Upside: +256.47%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $33.38
Upside: +34.81%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $29.78
Upside: +88.05%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $29.03
Upside: +192.85%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.20
Upside: +545.16%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $227.19
Upside: -82.39%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.94
Upside: +240.14%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.80
Upside: +66.67%